Background: It is known that metabolic syndrome characterized by diabetes, hypertension, dyslipidemia, and central obesity is associated with the syndrome of early vessels aging, characterized by a change in elasticity of the vessel wall. The early manifestation of the metabolic syndrome in younger people in the modern society, leads to earlier manifestation of the complications of early vessels aging, and the combination of several risk factors is crucial and leads to acceleration of the vessels aging. Elastin is one of the main building blocks of the of the vessel wall. Its main characteristic is its elasticity, allowing the vessel to restore its shape after stretching or shrinking. Loss of elasticity is a key component in the pathogenesis of cardiovascular complications.
BACKGROUND:
It is known that metabolic syndrome characterized by diabetes, hypertension, dyslipidemia, and central obesity is associated with the syndrome of early vessels aging, characterized by a change in elasticity of the vessel wall. The early manifestation of the metabolic syndrome in younger people in the modern society, leads to earlier manifestation of the complications of early vessels aging, and the combination of several risk factors is crucial and leads to acceleration of the vessels aging. Elastin is one of the main building blocks of the of the vessel wall. Its main characteristic is its elasticity, allowing the vessel to restore its shape after stretching or shrinking. Loss of elasticity is a key component in the pathogenesis of cardiovascular complications.
Number of studies have shown that the immune system reflects the physiological changes in the elastin metabolism in the vascular wall. In the recent years, using immunological methods, changes in elastin metabolism is examined, as a sign of vascular aging in high-risk subjects with cardiovascular complications.
There isn't sufficient information about the nature of the immune response against tropoelastin and elastin metabolism in patients with metabolic syndrome without cardiovascular complications. The data on the prognostic value in the evaluation process of early vascular aging is scarce. Therefore, the attempt to determine the changes in elastin and tropoelastin metabolism in metabolic syndrome DOI: 10.5272/jimab.2012183.345 is one of the first steps to seek early immunological rather than instrumental criteria to evaluate changes of the vascular wall.
MATERIALS AND METHODS:
A study is conducted on 62 subjects with metabolic syndrome without vascular complications and 42 controls.
The main objective of the study was to compare the imunological markers of elastin degradation in both groups and to assess their relationship with the risk factors characterizing the metabolic syndrome.
RESULTS:
When comparing the average AEAb IgG in the control group and subjects with metabolic syndrome (respectively 0.45 + / -0.11 and 0.54 + / -0.29) was determined statistically significantly higher mean values of AEAb IgG in the group with metabolic syndrome, t = -1,85, p = 0.03, Figure. 
CONCLUSION:
The changes in the immunological markers against elastin and tropoelastin, showed that antibodies from class IgG, characterising the secondary immune response, are elevated in the long-term chronic inflammation characterising the metabolic syndrome and atherosclerosis, respectively, the vascular aging process. Therefore, the constellation of elevated AEAb IgG, ATEAb IgG, can be used as an early marker of vascular aging.
The following conclusion can be made: dyslipidemia and its inherent hypertriglyceridemia is one of the laboratory criteria for metabolic syndrome, Characterising the increased insulin resistancy. Increased insulin resistancy affects the turnover of elastin and tropoelastin. The correlation between elevated levels of AEAb IgG, ATEAb IgG, and triglycerides adequately reflects the process of vascular aging, apparently orchestrated by insulin resistance and therefore can be discussed as a constellation, which is a sure sign of early vascular aging.
